Pyrotinib Maleate, Trastuzumab, SHR6390 and Letrozole in Combination for Stage II-III TPBC
Clinical trial NCT05228951 · RECRUITING
Trial details
- NCT number
- NCT05228951
- Sponsor
- Shengjing Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-02-10
- Primary completion
- 2022-12-31
- Enrollment
- 12
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.